Impact of sex, age at onset, and anti-cN1A antibodies on sporadic inclusion body myositis

被引:0
|
作者
Yamashita, Satoshi [1 ,2 ]
Tawara, Nozomu [1 ]
Sugie, Kazuma [3 ]
Suzuki, Naoki [4 ]
Nishino, Ichizo [5 ]
Aoki, Masashi [4 ]
机构
[1] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan
[2] Int Univ Hlth & Welf, Narita Hosp, Dept Neurol, 852 Hatakeda, Narita, Chiba 2868520, Japan
[3] Nara Med Univ, Sch Med, Dept Neurol, Kashihara, Japan
[4] Tohoku Univ, Grad Sch Med, Dept Neurol, Sendai, Japan
[5] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Kodaira, Japan
基金
日本学术振兴会;
关键词
Sporadic inclusion body myositis (IBM); Ages at onset; Disease duration; Gender; Cytoplasmic 5 '-nucleotidase 1 a autoantibody; CYTOSOLIC 5'-NUCLEOTIDASE 1A; ALZHEIMERS-DISEASE; CLINICAL-FEATURES; AUTOANTIBODIES;
D O I
10.1016/j.jns.2024.123164
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Inclusion body myositis (IBM) is a progressive myopathy occurring in patients over 45 years of age, with heterogeneous and variable clinical features. This study aimed to determine the influence of autoantibodies, gender, and age of onset on the clinical features of IBM. Methods: Medical records and muscle histology findings of 570 participants with suspected IBM were reviewed. Various characteristics of patients who met the 2011 ENMC IBM diagnostic criteria were compared based on the presence of anti-cytosolic 5 '-nucleotidase 1 A (cN1A) autoantibodies, gender, age of onset, and disease duration. Results: Of the 353 patients who met the criteria, 41.6% were female. The mean age at onset was 64.6 +/- 9.3 years, and the mean duration from onset to diagnosis was 5.7 +/- 4.7 years. 196 of the 353 patients (55.5%) were positive for anti-cN1A autoantibodies and 157 were negative. Logistic regression showed that patients with anticN1A autoantibodies had a higher frequency of finger flexion weakness. Multiple regression showed that patients with later age of onset had shorter disease duration, lower BMI, and lower serum CK levels. Male patients had a higher frequency of onset with finger weakness and female patients had a lower BMI. Conclusion: Autoantibodies, gender, age of onset, and disease duration may influence the clinical presentation of IBM, highlighting the need for a precision medicine approach that considers these factors along with the underlying mechanisms of the disease.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis
    Lucchini, Matteo
    Maggi, Lorenzo
    Pegoraro, Elena
    Filosto, Massimiliano
    Rodolico, Carmelo
    Antonini, Giovanni
    Garibaldi, Matteo
    Valentino, Maria Lucia
    Siciliano, Gabriele
    Tasca, Giorgio
    De Arcangelis, Valeria
    De Fino, Chiara
    Mirabella, Massimiliano
    CELLS, 2021, 10 (05)
  • [2] The utility of anti-cN1A autoantibody for the diagnosis of sporadic inclusion body myositis
    Nihimura, H.
    Suzuki, S.
    Noguchi, S.
    Uruha, A.
    Mitsuhashi, S.
    Hayashi, Y. K.
    Nonaka, I.
    Nishino, I.
    NEUROMUSCULAR DISORDERS, 2014, 24 (9-10) : 815 - 815
  • [3] Pathogenic role of anti-cN1A autoantibodies in sporadic inclusion body myositis
    Yamashita, Satoshi
    Tawara, Nozomu
    Zhang, Ziwei
    Nakane, Shunya
    Sugie, Kazuma
    Suzuki, Naoki
    Nishino, Ichizo
    Aoki, Masashi
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2023, 94 (12): : 1018 - 1024
  • [4] On the role of anti-cN1A antibodies in sporadic inclusion body myositis and beyond: a challenging task full of surprises
    Patrikiou, Eleni
    Liaskos, Christos
    Bogdanos, Dimitrios P.
    REUMATOLOGIA, 2023, 61 (06): : 411 - 413
  • [5] Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis
    Salam, S.
    Dimachkie, M. M.
    Hanna, M. G.
    Machado, P. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (02) : 384 - 393
  • [6] DIAGNOSTIC UTILITY OF ANTI-CN1A AUTOANTIBODY TESTING IN SPORADIC INCLUSION BODY MYOSITIS
    Al-Attar, Mariam
    Khoo, Thomas
    Lilleker, James B.
    Chinoy, Hector
    RHEUMATOLOGY, 2024, 63
  • [7] Diagnostic utility of anti-cN1A autoantibody testing in sporadic inclusion body myositis
    Al-Attar, Mariam
    Khoo, Thomas
    Lilleker, James B.
    Chinoy, Hector
    RHEUMATOLOGY, 2024, 63
  • [8] IMPLICATIONS OF ANTI-CN1A SEROTYPE IN INCLUSION BODY MYOSITIS
    Lilleker, James
    Rietveld, Anke
    Pye, Stephen
    Lamb, Janine
    Roberts, Mark
    Cooper, Robert
    Pruijn, Ger
    Chinoy, Hector
    van Engelen, Baziel
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 (12):
  • [9] Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis
    Paul, Pritikanta
    Liewluck, Teerin
    Ernste, Floranne C.
    Mandrekar, Jay
    Milone, Margherita
    MUSCLE & NERVE, 2021, 63 (04) : 490 - 496
  • [10] Predominant atrophy in type 2 myofibers of sporadic inclusion body myositis with anti-cn1a autoantibody
    Tawara, N.
    Yamashita, S.
    Zhang, X.
    Zhang, Z.
    Doki, T.
    Matsuo, Y.
    Nakane, S.
    Maeda, Y.
    Ando, Y.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 1079 - 1080